"Designing Growth Strategies is in our DNA"

Human Immunodeficiency Virus (HIV) Treatment Market Size, Share and Global Trend By Drug Class (Non-nucleoside reverse transcriptase inhibitors (NNRTIs), Nucleoside and nucleotide reverse transcriptase inhibitors (NRTIs), Protease Inhibitors (PIs), Integrase Inhibitor, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies) and Regional Forecast, 2024-2032

Region :Global | Report ID: FBI101245 | Status : Ongoing

 

KEY MARKET INSIGHTS

Human Immunodeficiency Virus (HIV) disease is a major global health issue. Human Immunodeficiency Virus (HIV) is a virus that leads to condition known as Acquired Immunodeficiency Syndrome (AIDS). Human Immunodeficiency Virus (HIV) attacks the body’s immune system specifically the CD4 cells (T cells), which help the immune system to fight against infections.


Absence of these CD4 cells, renders the body’s immune system inefficient to fight against chronic and acute diseases. Currently available treatment options are inefficient to completely cure the disease. Antiretroviral therapy (ART) is used as a treatment of Human Immunodeficiency Virus (HIV). Antiretroviral therapy (ART) slows down the progression of HIV in the body.

To gain extensive insights into the market, Request for Customization


There is an increasing effort being undertaken by regional and national governments, and non-profit organizations, to promote awareness regarding Human Immunodeficiency Virus (HIV) disease, and to eradicate the social stigma associated with the disease. This is aimed towards increasing diagnosis rate of Human Immunodeficiency Virus (HIV) among patients in emerging countries.

These initiatives are anticipated to present a comparatively larger pool of people undergoing diagnosis for HIV, and subsequently fuel the demand for Human Immunodeficiency Virus (HIV) drugs during the forecast period. This along with increasing prevalence of Human Immunodeficiency Virus (HIV) disease in emerging countries including China, India, and African countries, are factors projected to drive the growth of the global human immunodeficiency virus (HIV) treatment market during 2019-2026.

According to World Health Organization (WHO) in 2017 estimated 36.9 million people were infected with Human Immunodeficiency Virus (HIV) globally, however only 21.7 million people received treatment. Major factors attributed to this were lack of diagnosed HIV patients, high cost of Human Immunodeficiency Virus (HIV) drugs & social stigma. These are some major factors restraining the growth of human immunodeficiency virus (HIV) treatment market.

Key Players Covered


Some of the major companies that are present in the global human immunodeficiency virus (HIV) treatment market are Abbott, Pfizer Inc., Novartis AG, Sanofi, GlaxoSmithKline plc., Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Gilead Sciences, Inc., ViiV Healthcare and other players.

SEGMENTATION






















SEGMENTATION


 DETAILS


By Drug Class


· Non-nucleoside reverse transcriptase inhibitors (NNRTIs)

· Nucleoside and nucleotide reverse transcriptase inhibitors (NRTIs)

· Protease Inhibitors (PIs)

· Integrase Inhibitor

· Others


By Distribution Channel


· Hospital Pharmacies

· Retail Pharmacies

· Others


By Geography


· North America (USA and Canada)

· Europe (UK, Germany, France, Italy, Spain, Scandinavia and Rest of Europe)

· Asia Pacific (Japan, China, India, Australia, Southeast Asia and Rest of Asia Pacific)

· Latin America (Brazil, Mexico and Rest of Latin America)

· Middle East & Africa (South Africa, GCC and Rest of Middle East & Africa)


 

Key Insights



  • Pipeline Analysis, Key Players / Region

  • New Initiatives Undertaken by Government & Non-Government Organizations, Key Countries.

  • Pricing Analysis, Key Players, 2018

  • Key Mergers and Acquisitions.

  • Prevalence of Human Immunodeficiency Virus (HIV) Disease, Key Countries.


Regional Analysis


The global human immunodeficiency virus (HIV) treatment market has been segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa. North America dominates the global human immunodeficiency virus (HIV) treatment market in 2018. In U.S, the Centers for Disease Control and Prevention sponsored a campaign that motivated people to get tested for HIV. This campaign resulted in increased number of diagnosed HIV patients and subsequently increased demand for treatment in U.S. In Middle East & Africa, human immunodeficiency virus (HIV) treatment market is projected to grow at a comparatively higher CAGR during 2019-2026. This region contains a large population of HIV patients in comparison with other regions. Undiagnosed HIV patients and low per capita healthcare expenditure are the major reasons restraining the growth of the market in this region. However, government initiatives to provide low-cost treatment in this region, is expected to drive the growth of the market during 2019-2026.

Key Industry Developments



  • In 2018, researchers from Massachusetts Institute of Technology developed a capsule that was able to deliver a week worth of HIV drug in a single dose. This lead to increase in patient’s compliance for Antiretroviral Therapy.

  • First in human (FIH) clinical trial was held by Zion Medical in 2018, which found that the synthetic peptide drug (Gammora) reduced the level of viral RNA in patients’ blood up to 90% after five weeks. When given in combination with the approved HIV drugs: lopinavir and ritonavir, it reduced viral RNA levels up to 99% after five weeks.

  • In Aug 2018, Merck & Co., Inc. announced that FDA approved its two new antiretroviral drugs named Delstrigo & Pifetro that helped in treatment of HIV-1, the most common strain of virus.

  • In 2018 FDA approved Biktarvy, a daily single dose HIV medication by Gilead Sciences. Biktarvy is specifically indicated as a complete regimen for the treatment of HIV-1 infection in adults who have no antiretroviral treatment history or to replace current antiretroviral regimen.

  • In 2019, Food and Drug Administration finalized two guidelines on PrEP to support the manufacturers developing a new version of Antiretroviral medications.





  • Ongoing
  • 2023
  • 2019-2022

Personalize this Research

  • Granular Research on Specified Regions or Segments
  • Companies Profiled based on User Requirement
  • Broader Insights Pertaining to a Specific Segment or Region
  • Breaking Down Competitive Landscape as per Your Requirement
  • Other Specific Requirement on Customization
Request Customization Banner

Healthcare Clients

uniliver
abbvie
Amgen
Siemens Healthineers
Fresenius

Client Testimonials

“We are quite happy with the methodology you outlined. We really appreciate the time your team has spent on this project, and the efforts of your team to answer our questions.”

- One of the largest & renowned medical research centers based in the U.S. on a report on the U.S. NIPT Market.

“Thanks a million. The report looks great!”

- Feedback from a consultant on a report on the U.S. Beef Market.

“Thanks for the excellent report and the insights regarding the lactose market.”

- Brazil based company specializing in production of protein ingredients.

“I liked the report; would it be possible to send me the PPT version as I want to use a few slides in an internal presentation that I am preparing.”

- Global Digital Services Agency on a report on the Global Luxury Goods Market.

“This report is really well done and we really appreciate it! Again, I may have questions as we dig in deeper. Thanks again for some really good work.”

- U.S.-based biotechnology company focussing on treatment of chronic pain.

“Kudos to your team. Thank you very much for your support and agility to answer our questions.”

- Europe-based provider of solutions to automate data centre operations.

“We appreciate you and your team taking out time to share the report and data file with us, and we are grateful for the flexibility provided to modify the document as per request. This does help us in our business decision making. We would be pleased to work with you again, and hope to continue our business relationship long into the future.”

- India-based manufacturer of industrial and specialty intermediates with a strong global presence.

“I want to first congratulate you on the great work done on the Medical Platforms project. Thank you so much for all your efforts.”

- One of the largest cosmetics company in the world.

“Thank you very much. I really appreciate the work your team has done. I feel very comfortable recommending your services to some of the other startups that I’m working with, and will likely establish a good long partnership with you.”

- U.S. based startup operating in the cultivated meat market.

“We received the below report on the U.S. market from you. We were very satisfied with the report.”

- Global hearing aids manufacturer.

“I just finished my first pass-through of the report. Great work! Thank you!”

- U.S. based solar racking solutions provider.

“Thanks again for the great work on our last partnership. We are ramping up a new project to understand the imaging and imaging service and distribution market in the U.S.”

- World’s leading advisory firm.

“We feel positive about the results. Based on the presented results, we will do strategic review of this new information and might commission a detailed study on some of the modules included in the report after end of the year. Overall we are very satisfied and please pass on the praise to the team. Thank you for the co-operation!”

- Germany based machine construction company.

“Thank you very much for the very good report. I have another requirement on cutting tools, paper crafts and decorative items.”

- Japanese manufacturing company of stationery products.

“We are happy with the professionalism of your in-house research team as well as the quality of your research reports. Looking forward to work together on similar projects”

- One of the Leading Food Companies in Germany

“We appreciate the teamwork and efficiency for such an exhaustive and comprehensive report. The data offered to us was exactly what we were looking for. Thank you!”

- Intuitive Surgical

“I recommend Fortune Business Insights for their honesty and flexibility. Not only that they were very responsive and dealt with all my questions very quickly but they also responded honestly and flexibly to the detailed requests from us in preparing the research report. We value them as a research company worthy of building long-term relationships.”

- Major Food Company in Japan

“Well done Fortune Business Insights! The report covered all the points and was very detailed. Looking forward to work together in the future”

- Ziering Medical

“It has been a delightful experience working with you guys. Thank you Fortune Business Insights for your efforts and prompt response”

- Major Manufacturer of Precision Machine Parts in India

“I had a great experience working with Fortune Business Insights. The report was very accurate and as per my requirements. Very satisfied with the overall report as it has helped me to build strategies for my business”

- Hewlett-Packard

“This is regarding the recent report I bought from Fortune Business insights. Remarkable job and great efforts by your research team. I would also like to thank the back end team for offering a continuous support and stitching together a report that is so comprehensive and exhaustive”

- Global Management Consulting Firm

“Please pass on our sincere thanks to the whole team at Fortune Business Insights. This is a very good piece of work and will be very helpful to us going forward. We know where we will be getting business intelligence from in the future.”

- UK-based Start-up in the Medical Devices Sector

“Thank you for sending the market report and data. It looks quite comprehensive and the data is exactly what I was looking for. I appreciate the timeliness and responsiveness of you and your team.”

- One of the Largest Companies in the Defence Industry
We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies . Privacy.
X